Review
Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis
Eficacia y seguridad clínica del ixekizumab para el tratamiento de la psoriasis
Read
7666
Timeswas read the article
2202
Total PDF
5464
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 137 | 14 | 151 |
| 2025 5 | 185 | 32 | 217 |
| 2025 4 | 166 | 36 | 202 |
| 2025 3 | 172 | 21 | 193 |
| 2025 2 | 228 | 33 | 261 |
| 2025 1 | 110 | 25 | 135 |
| 2024 12 | 121 | 27 | 148 |
| 2024 11 | 117 | 67 | 184 |
| 2024 10 | 76 | 31 | 107 |
| 2024 9 | 70 | 24 | 94 |
| 2024 8 | 97 | 58 | 155 |
| 2024 7 | 96 | 26 | 122 |
| 2024 6 | 96 | 35 | 131 |
| 2024 5 | 65 | 32 | 97 |
| 2024 4 | 95 | 46 | 141 |
| 2024 3 | 88 | 36 | 124 |
| 2024 2 | 69 | 30 | 99 |
| 2024 1 | 57 | 34 | 91 |
| 2023 12 | 77 | 26 | 103 |
| 2023 11 | 90 | 27 | 117 |
| 2023 10 | 61 | 26 | 87 |
| 2023 9 | 53 | 36 | 89 |
| 2023 8 | 49 | 15 | 64 |
| 2023 7 | 50 | 32 | 82 |
| 2023 6 | 49 | 26 | 75 |
| 2023 5 | 76 | 23 | 99 |
| 2023 4 | 57 | 26 | 83 |
| 2023 3 | 85 | 25 | 110 |
| 2023 2 | 58 | 18 | 76 |
| 2023 1 | 37 | 33 | 70 |
| 2022 12 | 73 | 55 | 128 |
| 2022 11 | 48 | 35 | 83 |
| 2022 10 | 33 | 25 | 58 |
| 2022 9 | 50 | 29 | 79 |
| 2022 8 | 61 | 30 | 91 |
| 2022 7 | 26 | 41 | 67 |
| 2022 6 | 39 | 40 | 79 |
| 2022 5 | 77 | 24 | 101 |
| 2022 4 | 95 | 43 | 138 |
| 2022 3 | 101 | 59 | 160 |
| 2022 2 | 108 | 39 | 147 |
| 2022 1 | 117 | 47 | 164 |
| 2021 12 | 92 | 34 | 126 |
| 2021 11 | 71 | 37 | 108 |
| 2021 10 | 93 | 57 | 150 |
| 2021 9 | 87 | 32 | 119 |
| 2021 8 | 97 | 34 | 131 |
| 2021 7 | 78 | 21 | 99 |
| 2021 6 | 101 | 27 | 128 |
| 2021 5 | 51 | 41 | 92 |
| 2021 4 | 131 | 65 | 196 |
| 2021 3 | 99 | 31 | 130 |
| 2021 2 | 70 | 39 | 109 |
| 2021 1 | 38 | 20 | 58 |
| 2020 12 | 42 | 23 | 65 |
| 2020 11 | 39 | 26 | 65 |
| 2020 10 | 26 | 6 | 32 |
| 2020 9 | 33 | 11 | 44 |
| 2020 8 | 30 | 19 | 49 |
| 2020 7 | 28 | 11 | 39 |
| 2020 6 | 31 | 27 | 58 |
| 2020 5 | 19 | 8 | 27 |
| 2020 4 | 18 | 15 | 33 |
| 2020 3 | 18 | 13 | 31 |
| 2020 2 | 5 | 0 | 5 |
| 2020 1 | 2 | 0 | 2 |
| 2019 12 | 5 | 0 | 5 |
| 2019 11 | 3 | 0 | 3 |
| 2019 9 | 4 | 0 | 4 |
| 2019 8 | 4 | 0 | 4 |
| 2019 7 | 8 | 0 | 8 |
| 2019 6 | 13 | 0 | 13 |
| 2019 5 | 2 | 1 | 3 |
| 2019 4 | 5 | 2 | 7 |
| 2019 2 | 3 | 0 | 3 |
| 2018 12 | 5 | 0 | 5 |
| 2018 11 | 3 | 0 | 3 |
| 2018 10 | 6 | 0 | 6 |
| 2018 9 | 4 | 0 | 4 |
| 2018 5 | 1 | 0 | 1 |
| 2018 4 | 2 | 1 | 3 |
| 2018 2 | 47 | 6 | 53 |
| 2018 1 | 52 | 6 | 58 |
| 2017 12 | 41 | 9 | 50 |
| 2017 11 | 50 | 14 | 64 |
| 2017 10 | 59 | 17 | 76 |
| 2017 9 | 33 | 43 | 76 |
| 2017 8 | 41 | 42 | 83 |
| 2017 7 | 37 | 18 | 55 |
| 2017 6 | 46 | 15 | 61 |
| 2017 5 | 66 | 38 | 104 |
| 2017 4 | 10 | 6 | 16 |
Show all
